Urinary Stress IncontinenceNCT03881293
Effects of Topical Lidocaine During Urodynamic Testing In Women
A study testing lidocaine 2% gel and water soluble lubricant in people with Urinary Stress Incontinence and Pain, run by Kristine Zinkgraf.
Trial summary
Urodynamic testing is used to help diagnose causes of urinary incontinence and voiding dysfunction. The purpose of the urodynamic test is to gain insight into the patient's urinary symptoms and assist in making a diagnosis. Catheter insertion and manipulation during the test can be uncomfortable for the patient. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Urinary Stress Incontinence, Pain
- What is being tested?
- lidocaine 2% gel and water soluble lubricant
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 110 participants
- Where
- No sites listed yet
- Study dates
- Dec 2013to Dec 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Women with complaint of stress urinary incontinence who were scheduled for a urodynamic test Patients with symptomatic pelvic organ prolapse if they also had stress incontinence symptoms.
- Community dwelling elderly patients who were able to provide their own history and were able to sign for themselves
Who cannot join
- Patients who were unable to provide their own consent Patients who are allergic to lidocaine Children and pregnant patients
About this study
Urodynamic testing is used to help diagnose causes of urinary incontinence and voiding dysfunction. The purpose of the urodynamic test is to gain insight into the patient's urinary symptoms and assist in making a diagnosis. Catheter insertion and manipulation during the test can be uncomfortable for the patient. Lidocaine gel has not been used routinely during urodynamic testing. However, it is used routinely during outpatient cystoscopy and with any urethral catheterization. The investigators proposed that lidocaine numbing gel could be used without compromising test findings.
The study included 110 adult women. The purpose was:
- Determine whether the use of topical lidocaine during urodynamic testing decreases patient discomfort during the procedure.
- Evaluate whether the use of topical lidocaine affects the urodynamic results.
Read the detailed description
Topical Lidocaine For Urodynamic Testing: A Double Blinded Randomized Control Trial
Hypothesis / aims of study
- Determine whether the use of topical lidocaine during urodynamic testing decreases patient discomfort during the procedure.
- Evaluate whether the use of topical lidocaine affects the urodynamic results.
Study design, materials and methods The hospital IRB approved the study. Women with symptoms of stress urinary incontinence (SUI) scheduled for a urodynamic study (UDS) were eligible to participate. Women presenting with predominant overactive bladder symptoms were excluded. Participants were randomized on the day of the procedure using Random Allocation Software Version 1.0. All were blinded to the study arms until completion of final data analysis. Participant randomization assignment was known only to an independent research nurse and the dispensing pharmacist. The study consisted of transurethral administration of 5 ml lidocaine 2% gel or surgilube gel, in the study and control arms, respectively, 10 minutes before catheter insertion. Prior to testing, a 24 hour bladder diary and the Pelvic Floor Distress Inventory - Short Form 20 were completed. During the UDS participants were asked for sensory information including desire to void and maximal cystometric capacity (MCC). Urethral pressure profiles were obtained at an infused volume of 200 ml. Provocative measures were performed to assess SUI. Using a Likert scale, pain was assessed prior to and after catheter insertion, after performing the urethral pressure profile, and at the completion of the study. The primary outcome; pain after urethral pressure profile (UPP), was compared between the two groups. Comparisons of the bladder diary and UDS results were made between study and control arms individually and in-between groups.
Statistical methods The effect of lidocaine on patient pain as reported during multiple time-points during the UDS was evaluated using repeated measures analysis via mixed effects regression with a random patient-specific intercept. This approach allows the evaluation of the overall pain experience, as well as baseline-adjusted comparison at individual time-points. Comparisons were done using t-tests for continuous variables, Chi-squared test for categorical variables, Wilcoxon rank-sum test, Lin's Concordance Correlation Coefficient (CCC), and a z-test. The CCC provides a generalization of Pearson's correlation coefficient that measures how well the data align with the diagonal representing equal values for the two measurements (as opposed to any straight line). Agreement is stronger than correlation. Specifically, the agreement between mean void volume and volume at strong desire, as well as between maximum void volume and volume at MCC were computed separately for each study group. The CCC values were compared between the study groups using a z-test. Power calculations determined a total sample size of 110 participants was needed to detect significant differences between the groups with at least 94% statistical power.
- Conditions
- Urinary Stress Incontinence, Pain
- Being tested
- lidocaine 2% gel, water soluble lubricant
- Keywords
- urodynamics, women, lidocaine gel
- Medical subject headings
- Urinary Incontinence, Stress, Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
lidocaine 2% gelDrug
Transurethral instillation of 5 ml lidocaine 2% gel
water soluble lubricantDrug
Transurethral instillation of 5 ml water soluble lubricant
| Study group | Role | What they receive |
|---|---|---|
| Placebo Lubricant Gel | Placebo comparator | 5 ml water-soluble gel instilled transurethrally ten minutes prior to catheter insertion Receives: Drug: water soluble lubricant |
| Lidocaine 2% Gel | Active comparator | 5 ml lidocaine 2% gel instilled transurethrally ten minutes prior to catheter insertion Receives: Drug: lidocaine 2% gel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in pain immediately after urethral pressure profilometry
Patient rated pain using Likert Scale of 0-10 (0 is no pain and 10 is worst pain)
Measured: Pain was assessed immediately after urethral pressure profilometry was performed
Secondary outcomes (2)
Demonstration of stress urinary incontinence during the urodynamic test
Ability to demonstrate stress urinary incontinence during the urodynamic test
Measured: During the urodynamic test
Perception of bladder filling
Correlation of maximal cystometric capacity on urodynamic test and maximal voided volume on bladder diary
Measured: During the urodynamic test
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2019
- Study startDec 2013
- Primary completionDec 2016
- Study completionDec 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Urinary Stress IncontinenceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Double Blinded Randomized Control Trial
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 110 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kristine Zinkgraf
- Sponsor type
- University, hospital or other
- Collaborators
- Medical College of Wisconsin, WomenConnected
- Responsible party
- Sponsor-investigator, Kristine Zinkgraf, ProHealth Care, Inc
- Investigators
- Katherine Stevenson, MD, Principal investigator, ProHealth Care
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03881293
- Sponsor's protocol ID
- IRB#12-09
- Status last verified
- Mar 2019
- First submitted
- 15 Feb 2019
- Last updated
- 19 Mar 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Topical Lidocaine During Urodynamic Testing In Women
- ClinicalTrials.gov ID
- NCT03881293
- Acronym / sponsor ID
- IRB#12-09
- Conditions
- Urinary Stress Incontinence, Pain
- Keywords
- urodynamics, women, lidocaine gel
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 110 participants (actual)
- Lead sponsor
- Kristine ZinkgrafUniversity, hospital or other
- Collaborators
- Medical College of Wisconsin, WomenConnected
- Study start
- Dec 2013 (actual)
- Primary completion
- Dec 2016 (actual)
- Study completion
- Dec 2016 (actual)
- First posted
- 19 Mar 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Urodynamic testing is used to help diagnose causes of urinary incontinence and voiding dysfunction. The purpose of the urodynamic test is to gain insight into the patient's urinary symptoms and assist in making a diagnosis. Catheter insertion and manipulation during the test can be uncomfortable for the patient. Lidocaine gel has not been used routinely during urodynamic testing. However, it is used routinely during outpatient cystoscopy and with any urethral catheterization. The investigators proposed that lidocaine numbing gel could be used without compromising test findings.
The study included 110 adult women. The purpose was:
- Determine whether the use of topical lidocaine during urodynamic testing decreases patient discomfort during the procedure.
- Evaluate whether the use of topical lidocaine affects the urodynamic results.
Detailed description
Topical Lidocaine For Urodynamic Testing: A Double Blinded Randomized Control Trial
Hypothesis / aims of study
- Determine whether the use of topical lidocaine during urodynamic testing decreases patient discomfort during the procedure.
- Evaluate whether the use of topical lidocaine affects the urodynamic results.
Study design, materials and methods The hospital IRB approved the study. Women with symptoms of stress urinary incontinence (SUI) scheduled for a urodynamic study (UDS) were eligible to participate. Women presenting with predominant overactive bladder symptoms were excluded. Participants were randomized on the day of the procedure using Random Allocation Software Version 1.0. All were blinded to the study arms until completion of final data analysis. Participant randomization assignment was known only to an independent research nurse and the dispensing pharmacist. The study consisted of transurethral administration of 5 ml lidocaine 2% gel or surgilube gel, in the study and control arms, respectively, 10 minutes before catheter insertion. Prior to testing, a 24 hour bladder diary and the Pelvic Floor Distress Inventory - Short Form 20 were completed. During the UDS participants were asked for sensory information including desire to void and maximal cystometric capacity (MCC). Urethral pressure profiles were obtained at an infused volume of 200 ml. Provocative measures were performed to assess SUI. Using a Likert scale, pain was assessed prior to and after catheter insertion, after performing the urethral pressure profile, and at the completion of the study. The primary outcome; pain after urethral pressure profile (UPP), was compared between the two groups. Comparisons of the bladder diary and UDS results were made between study and control arms individually and in-between groups.
Statistical methods The effect of lidocaine on patient pain as reported during multiple time-points during the UDS was evaluated using repeated measures analysis via mixed effects regression with a random patient-specific intercept. This approach allows the evaluation of the overall pain experience, as well as baseline-adjusted comparison at individual time-points. Comparisons were done using t-tests for continuous variables, Chi-squared test for categorical variables, Wilcoxon rank-sum test, Lin's Concordance Correlation Coefficient (CCC), and a z-test. The CCC provides a generalization of Pearson's correlation coefficient that measures how well the data align with the diagonal representing equal values for the two measurements (as opposed to any straight line). Agreement is stronger than correlation. Specifically, the agreement between mean void volume and volume at strong desire, as well as between maximum void volume and volume at MCC were computed separately for each study group. The CCC values were compared between the study groups using a z-test. Power calculations determined a total sample size of 110 participants was needed to detect significant differences between the groups with at least 94% statistical power.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Double Blinded Randomized Control Trial
| Arm | Type | Receives |
|---|---|---|
| Placebo Lubricant Gel | Placebo comparator | Drug: water soluble lubricant5 ml water-soluble gel instilled transurethrally ten minutes prior to catheter insertion |
| Lidocaine 2% Gel | Active comparator | Drug: lidocaine 2% gel5 ml lidocaine 2% gel instilled transurethrally ten minutes prior to catheter insertion |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Women with complaint of stress urinary incontinence who were scheduled for a urodynamic test Patients with symptomatic pelvic organ prolapse if they also had stress incontinence symptoms.
- Community dwelling elderly patients who were able to provide their own history and were able to sign for themselves
Key exclusion criteria (1 listed)
- Patients who were unable to provide their own consent Patients who are allergic to lidocaine Children and pregnant patients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| lidocaine 2% gelTransurethral instillation of 5 ml lidocaine 2% gel | Drug | Lidocaine 2% Gel |
| water soluble lubricantTransurethral instillation of 5 ml water soluble lubricant | Drug | Placebo Lubricant Gel |
Primary outcome
Change in pain immediately after urethral pressure profilometry
Time frame: Pain was assessed immediately after urethral pressure profilometry was performed
Patient rated pain using Likert Scale of 0-10 (0 is no pain and 10 is worst pain)
2 secondary outcomes
Demonstration of stress urinary incontinence during the urodynamic test
Time frame: During the urodynamic test
Perception of bladder filling
Time frame: During the urodynamic test
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2019.
- Individual participant dataSharing planned: No
Related trials for Urinary Stress Incontinence
RecruitingPhase 3
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Urinary Incontinence,Stress
Active, not recruitingObservational study
Return to Physical Activity After Retropublic Transvaginal Sling and Laparoscopic Sacrocolpopexy
Stress Urinary Incontinence, Pelvic Organ Prolapse
RecruitingPhase 1
Allogeneic Use of Expanded Mesenchymal Stem Cells Derived From Adipose Tissue (HC106), Female Urinary Incontinence Women Over 50 Years Old
Urinary Incontinence Stress
Recruiting
The Application of Somatosensory Interactive Pelvic Floor Muscle Training for Stress Urinary Incontinence in Men Underwent Radical Prostatectomy
Prostate Cancer (Post Prostatectomy)
RecruitingObservational study
Standardized 4D Transperineal Ultrasound Assessment of Urethrovesical Junction Mobility After Vaginal Laser Treatment for Stress Urinary Incontinence.
Urinary Incontinence , Stress, Laser Therapy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Katherine Stevenson, MD principal investigator
ProHealth Care
Questions about this trial
What is this clinical trial studying?
A study testing lidocaine 2% gel and water soluble lubricant in people with Urinary Stress Incontinence and Pain, run by Kristine Zinkgraf.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in pain immediately after urethral pressure profilometry (time frame: Pain was assessed immediately after urethral pressure profilometry was performed). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2019.